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Introduction
Angiotensin-converting enzyme (ACE) inhibitors are 
commonly used in the management of hypertension, 
cerebrovascular disease, diabetes-associated nephropathy, 
heart failure and stable coronary heart disease.1 ACE 
inhibitors have been shown to improve the vascular 
endothelial function.1,2 They are often used in combination 
with diuretics and calcium-channel blockers. However, 
this class of drugs has side-effects, which, at times, can 
result in patients being non-compliant. Therefore, it is 
important for clinicians to be aware of these side-effects, 
so as to educate patients, and improve compliance. In 
the Perindopril Protection Against Recurrent Stroke Study 
(PROGRESS) trial, perindopril (an ACE inhibitor) was 
combined with indapamide (a diuretic), a combination 
which demonstrated better blood pressure control and 
reduced risk of stroke and vascular events when compared 
to perindopril alone.3 Withdrawal from this study was due 
to side-effects.3 In another study, the side-effects of ACE 
inhibitors, calcium-channel blockers, diuretics and beta 
blockers were compared. Results showed side-effects 
of 7% for ACE inhibitors, 5% for beta blockers, 4% for 
calcium-channel blockers, and 3% for diuretic treatment.4
In this paper, we discuss ACE inhibitors with reference to 
mechanism of action, indications, precautions, and side-
effects. Major side-effects will be discussed in detail. 
Mechanism of action 
ACE inhibitors inhibit the conversion of angiotensin I to 
angiotensin II, and the degradation of bradykinin.4 This 
inhibition reduces the level of angiotensin II, and increases 
the level of bradykinin in tissues (Figures 1 and 2). 
Angiotensin II is a vasoconstrictor, and increases intracellular 
adhesion molecule-1, vascular cell adhesion molecule-1, 
growth factors, oxyradical formation, plasminogen activator 
inhibitor-1, smooth muscle cell proliferation and matrix 
degradation. All of these result in endothelial dysfunction, 
inflammation, coagulation and atherogenesis (Figure 2). 
Angiotensin II also stimulates the adrenal cortex to release 
aldosterone, a hormone which causes salt and water 
retention and potassium excretion. Bradykinin causes 
vasodilation and increases nitric oxide, tissue plasminogen 
activator and prostacyclin, thus protecting the endothelium 
against the effects of angiotensin II. 
Indications 
ACE inhibitors are indicated in the management of patients 
with hypertension, heart failure, cerebrovascular disease, 
diabetes-associated nephropathy, coronary heart disease, 
and reduced left ventricular function, with ejection fraction 
of ≤ 35% without heart failure.1,5,6,7
Precautions
Clinicians should take precautionary measures when 
prescribing ACE inhibitors to patients with hypotension, 
heart failure, cardiac outflow obstruction, and impaired 
renal function, as well as to patients taking multiple 
antihypertensive medication.8 In such situations, patients 
should start taking a low dose of an ACE inhibitor. If they 
are on a diuretic, it may be necessary to stop taking it before 
starting to take an ACE inhibitor.8 
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Abstract
Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs commonly used in the management of hypertension, 
congestive heart failure, cerebrovascular disease, stable coronary heart disease and diabetes-associated nephropathy. 
ACE inhibitors are divided into three classes, namely sulphydryl-containing ACE inhibitors structurally related to captopril, 
carboxyl-containing ACE inhibitors structurally related to enalapril, and phosphorus-containing ACE inhibitors structurally 
related to fosinopril. Though these classes of drugs are important in the treatment of the above conditions, they are not 
without side-effects. It is very important for clinicians to be aware of these side-effects so that patients can be warned, and 
compliance can be improved.
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The side-effects of ACE inhibitors include the following: 
dry cough, angioedema, hypotension, acute renal 
failure, hyperkalaemia, glycosuria, foetopathic potential, 
hepatotoxicity, dysgeusia, vomiting, neutropenia, and 
skin rashes, such as maculopapular rash and erythema 
multiforme.5,7,8
Hypotension
The patient with ACE inhibitor-induced hypotension will 
present with a history of being on ACE inhibitors, and may 
experience dizziness, fatiguability, weakness, syncope, and/
or low blood pressure. Hypotension is common in patients 
whose renin-angiotensin system has been activated. These 
are patients with heart failure and those who are volume 
depleted, including patients on diuretic therapy. Black 
patients have low plasma renin activity, and respond poorly 
to ACE inhibitor monotherapy. When an ACE inhibitor 
is combined with a diuretic, the effect is the same as the 
response in those with increased plasma renin activity. 
Low-dose initial therapy is recommended for patients to 
whom an ACE inhibitor has to be given.2,8 If the patient is 
on diuretic therapy, it may be advisable to stop the diuretic 
therapy for about three to five days before initiating an ACE 
inhibitor-containing regimen.5,8









• Decrease NO activity: vasoconstriction
• Increase PAI 1: increase thrombosis
• Increase cGMP: apoptosis/remodelling
Angiotensin II receptors
Angiotensin-converting enzyme
NO: nitric oxide, PAI: plasminogen activator inhibitor 1, cGMP: cyclic guanosine monophosphate
Figure 1: Mechanism of action of angiotensin-converting enzyme inhibitors
t-PA: tissue plasminogen activator, ICAM-1: intercellular adhesion protein 1, VCAM-1: vascular cell adhesion protein 1
Figure 2: Atherosclerosis-promoting actions of angiotensin II and the protective effects of bradykinin
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Acute renal failure
Angiotensin II causes efferent (postglomerular) arteriolar 
constriction. This effect maintains intraglomerular pressure 
and the glomerular filtration rate. Blocking this effect with 
an ACE inhibitor reduces intraglomerular pressure, and 
decreases the glomerular filtration rate, resulting in acute 
renal failure. Patients at high risk of developing acute renal 
failure include those with bilateral renal artery stenosis, 
congestive cardiac failure, hypertensive nephrosclerosis, 
polycystic kidney disease, and chronic renal failure. In 
patients at risk of developing renal failure, renal function 
needs to be checked three to five days after starting an ACE 
inhibitor.8
Hyperkalaemia
Angiotensin II and the increase in plasma potassium 
concentration stimulate the release of aldosterone from 
the adrenal zona glomerulosa. Aldosterone is a hormone 
that increases the urinary excretion of potassium. Locally 
generated angiotensin II in the zona glomerulosa mediates 
potassium-induced aldosterone release. Blocking angio-
tensin II formation with an ACE inhibitor will reduce 
aldosterone release, and this will reduce potassium 
excretion, and therefore cause hyperkalaemia. As a side-
effect of an ACE inhibitor, hyperkalaemia is more common 
in patients with renal dysfunction, diabetes mellitus, 
concurrent use of an ACE inhibitor with potassium-sparing 
diuretics, and nonsteroidal anti-inflammatory drugs. In 
these patients, a low dose of an ACE inhibitor may lessen 
the development of hyperkalaemia.8
Dry cough
A dry cough is noted in 5-20% of patients on an ACE 
inhibitor.5,8 Patients may present with bronchospasm, and 
may be misdiagnosed with asthma. A cough may occur 
within one to two weeks of starting an ACE inhibitor. An 
ACE inhibitor-induced cough is more common in women 
than in men, and it usually resolves within one to four days 
of stopping therapy, but it can take up to four weeks to 
cease, or even longer.5,8 The cough recurs when the patient 
is rechallenged with the same, or a different, ACE inhibitor. 
In the Ongoing Telmisartan Alone and in Combination 
with Ramipril Global Endpoint Trial (ONTARGET), 4.2% 
of patients on ramipril stopped therapy permanently due 
to a dry cough.9 The mechanism of cough is not clear in 
these patients, but it is thought to be related to a high 
concentration of kinins, prostaglandins, thromboxane and 
substance P.9 The presence of a cough in some patients, 
and not in others, suggests that genetic factors may play 
a role. Treatment may involve cessation of the drug, or 
reduction of the dose.8 If the drug is stopped, and it is still 
necessary to use a renin-angiotensin system blockade, an 
angiotensin receptor blocker would be the drug of choice. 
Alternatively, depending on the clinical indication, a different 
class of drugs could be prescribed.8 
Angioedema
This is a rare, but potentially fatal, side-effect of ACE 
inhibitors. In the ONTARGET trial, 0.3% of patients on 
ramipril stopped the drug permanently due to angioedema.9 
The risk factors for the development of ACE inhibitor-
induced angioedema may be genetic, e.g. black race and 
female gender, or may be environmental, e.g. smoking.5 
Angioedema can occur after the first dose, or as late as two 
years after beginning treatment. The pathophysiology of 
angioedema in patients taking an ACE inhibitor is due to a 
decrease in bradykinin degradation. Aminopeptidase P and 
dipeptidyl peptidase P are important in the degradation of 
substance P, and when they are reduced, angioedema may 
occur.4,10 Clinical features of angioedema include swelling 
and oedema of the face (common), tongue, oropharynx, 
larynx and intestines. The oedema is mostly localised, non-
pruritic and non-pitting. Management strategies depend on 
the severity of angioedema at presentation. Drug therapies 
include glucocorticoids, antihistamines, and epinephrine. 
In severe cases, the patient may need intubation and 
mechanical ventilation.4,10,11
Conclusion
The side-effects of ACE inhibitors can cause non-
compliance in some patients. Sometimes, they can be 
life-threatening, as in severe angioedema. Therefore, it is 
important for clinicians to be aware of these side-effects, 
and to warn patients about them. This is important for 
patients’ safety and improvement of compliance.
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